Effects of corticosteroids in acute severe asthma

Most respiratory physicians would subscribe to the view that systemic corticosteroids are essential in the management of acute severe asthma, though there have been dissenting voices. Studies of asthma deaths have highlighted failure to use systemic corticosteroids as a risk factor for death from asthma. The recently published guidelines on the management of acute severe asthma emphasise the importance of systemic corticosteroids. Yet in this issue of Thorax two trials are reported of the use of corticosteroids in acute severe asthma that provide little evidence of any therapeutic effect. Can the apparent contradiction between the results of these and other trials showing no benefit for steroids in acute severe asthma and the widely held belief that they are essential be resolved? This requires an examination of our understanding of the pathogenesis of acute severe asthma, the mechanism of action of corticosteroids in asthma, and a review of published trials.

Pathophysiology of acute severe asthma

Concepts of the pathophysiology of chronic asthma have changed in the last two decades. Asthma is increasingly considered to be a disease of chronic airways inflammation subject to exacerbations caused by viruses, antigens, and non-specific irritants. These exacerbating factors lead to worsening of airways inflammation and the release of chemical mediators that cause airway smooth muscle spasm.

These basic mechanisms are reflected in the clinical presentation of acute severe asthma. Although some attacks present as sudden wheeze and shortness of breath “out of a clear blue sky,” most occur against a background of long term poorly controlled asthma or asthma that has been worsening for some days or even weeks. The treatment of acute severe asthma is therefore an important occasion to review the management of chronic asthma as advocated in the British Thoracic Society’s guidelines. In the management of chronic asthma the efficacy of treatment with both oral and inhaled corticosteroids is unequivocal.

When we are considering the role of systemic corticosteroids in the management of asthma in the patient with acute severe asthma, the role of other inflammatory mediators is often forgotten. Neutrophils are perhaps the most important cellular type. They are attracted to the site of the inflammation by cytokines and produce reactive oxygen species and proteolytic enzymes that can further damage the bronchial wall. The recruitment and activation of neutrophils are influenced by local levels of corticosteroids, which also act as potent inhibitors of their activation.

Mechanism of action of corticosteroids

Corticosteroids have a multitude of actions that may be potentially of benefit in asthma. They decrease inflammatory cell recruitment and activation, upregulate β2 receptors, and decrease microvascular permeability and they may decrease mucus production. In terms of molecular mechanism steroids are thought to act by binding to a glucocorticoid receptor, which is then activated and binds to the cell nucleus, on to the regulatory glucocorticoid receptor elements associated with several genes. These glucocorticoid response elements then up or down regulate production of messenger RNA (mRNA), which eventually leads to increases or decreases in protein production. The proteins affected include enzymes and cell surface receptors. Such a mechanism of action, with gene regulation and then protein synthesis, will obviously take some hours or even days to show a clinical effect. In view of these basic mechanisms early effects in acute severe asthma would not be anticipated.

Trials of corticosteroids in acute severe asthma

The natural history of acute severe asthma leads to either death or resolution. There is usually a natural tendency to improvement. In almost all trials of corticosteroids in acute severe asthma other effective anti-asthma treatment has also been given, including large doses of inhaled β2 agonists and in many studies intravenous or oral theophyllines. Most patients will already be taking anti-asthma treatment, including inhaled or oral corticosteroids. The effect of corticosteroids has to be seen over and above the natural tendency to improvement and the other effective treatments. There is also evidence for a variability in individual patients’ response to corticosteroids, which is well recognised clinically but will also lead to a scatter of responses in any clinical trial. Furthermore, most trials have followed patients for a short time, rarely exceeding three days and often as little as six hours. Given these factors and the small number of patients in some studies, it is not surprising that some trials have failed to identify a positive effect of corticosteroids.

Morrell et al, in a study of 90 patients split into three groups, have compared two doses of methylprednisolone (60 and 12 mg/kg/day) with placebo. Patients received a rather unconventional regimen of three doses of adrenaline within the first hour, intravenous aminophylline, and four hourly inhaled hexoprenaline (a β2 agonist) 5 mg. There was no difference in the rate of recovery of pulmonary function or arterial blood gas tensions between the three groups. In two subgroups—those already having oral steroids and those who did not achieve a 15% improvement in peak expiratory flow by the third hour of the study—there was a trend towards more rapid improvement with very high dose corticosteroids. Twenty eight per cent of patients were taking oral steroids on entry to the study, which may have blunted the ability to show an additional effect of steroids. Furthermore, the concomitant treatment with adrenaline, intravenous aminophylline and β2 agonists was very vigorous and might have made an additional effect of steroids difficult to detect. Bowler et al in a study of 66 patients with acute severe asthma compared three different doses of corticosteroids, but did not include a placebo group. They compared a “low” dose (hydrocortisone 50 mg six hourly), a “medium” dose (200 mg six hourly), and a “high” dose (500 mg six hourly) each given for 48 hours. All subjects received inhaled β2 agonists and theophylline. They showed no difference in the rate of recovery in lung function between the three groups.

Both Morrell et al and Bowler et al have failed to identify a dose-response relationship for corticosteroids in the treatment of acute severe asthma. This finding is similar to the results of other trials, where investigators have been unable to establish a dose-response relationship. Examining these studies in more detail shows that McFadden et al followed patients for only six hours, which is too short a time to show a significant effect. Other studies with negative results have probably investigated too few subjects, Harfi et al studying 21 children and Tanaka et al 10 adults. Raimondi et al studied 40 adults, investigating two doses of hydrocortisone (80 and 6 mg/kg day) over five days, and failed to show a difference. Haskell et al showed a dose-response relationship for three doses of methylprednisolone, with faster recovery in those having medium and high doses. In a small eight day study of 26 patients by Britton et al there was a tendency for the groups taking medium and high dose steroids to do better than the
low dose group. In a crossover study of treatment of deteriorating asthma treated on an outpatient basis an unequivocal dose-response relationship has been shown by Webb.

When trials have compared systemic corticosteroids with placebo they have usually had a positive result. In trials with negative results patients were studied for only six hours or discharge from the emergency room 12 hours after the start of treatment was the major endpoint. The various trials have used intravenous hydrocortisone, oral corticosteroids, or both. One study compared oral prednisolone (75 mg) plus placebo with prednisolone 75 mg, and intravenous hydrocortisone (3 mg/kg six hourly) and found no difference in peak expiratory flow rate at 24 hours. This result is predictable from our new knowledge about the absorption of oral steroids and the mode of action of steroids.

It is customary to end a review such as this by calling for further research to be undertaken; but the weight of evidence from clinical trials of steroids in acute severe asthma, the epidemiological studies, and clinical experience make trials investigating the efficacy of steroid versus placebo and the route of administration difficult to justify. Unresolved questions remain—namely, the dose and the duration of treatment. The trial design used will obviously depend on the question being asked but anyone who is tempted to perform a trial of corticosteroids in acute severe asthma should bear in mind the following: (a) ideally bronchodilator treatment that is in accordance with standard practice should be used in the study; (b) if more than two treatments are compared or multiple groups are used the power of the study will decrease unless numbers are large; (c) the longer the period of observation the better, up to perhaps one week being useful; and (d) including relapse rate after discharge as an endpoint may be helpful.

NC BARNES  
London Chest Hospital, London E2 9JX

16 Schleimer RP. Effects of glucocorticoids on inflammatory cells relevant to their therapeutic applications in asthma. Am Rev Respir Dis 1990;141:559-60.
Effects of corticosteroids in acute severe asthma.

N C Barnes

Thorax 1992 47: 582-583
doi: 10.1136/thx.47.8.582

Updated information and services can be found at:
http://thorax.bmj.com/content/47/8/582.citation

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/